What is the long-term trend for Medifast's cash cash equivalents and short term investments?

Over 3 years (2022 to 2025), Medifast's cash cash equivalents and short term investments has grown at a 23.8% compound annual growth rate (CAGR), from $87.69M to $166.35M.

Medifast MED Cash Cash Equivalents And Short Term Investments

Cash Cash Equivalents And Short Term Investments at other companies

AmphenolAPH

$4.58B+174%

Travel + LeisureTNL

$456M+24.3%

Warrior Met CoalHCC

$210.55M-54.5%

Main Street CapitalMAIN

$20.79M-81.0%

Cabot CorporationCBT

$252M+18.3%

HES

Hess MidstreamHESM

$4.6M-24.6%

Other financials

Income statement

See full

Revenue$76.0M-34.3%

Gross profit$51.8M-38.6%

Operating income-$3.3M-161%

Net income-$2.1M-175%

EPS (diluted)-$0.19-171%

Balance sheet

See full

Cash & equivalents$71.5M-22.0%

Total debt$16.1M+10.2%

Total equity$197.7M-6.3%

Total assets$252.0M-10.0%

Cash flow

See full

Operating cash flow$260.0K-92.4%

CapEx$1.1M-28.0%

Free cash flow-$836.0K-144%

Valuation

See full

Market cap$121.87M-17.4%

Enterprise value$66.44M+12.8%

P/S0.4×0.0×

Profitability

See full

Gross margin70.1%-3.8pp

Operating margin-4.7%-7.0pp

Net margin-5.8%-8.1pp

FCF margin5%-9.3pp

Returns & leverage

See full

Return on equity-9.8%-20.1pp

Debt / equity0.1×0.0×

Current ratio4.8×+1.3×

Where this comes from

Reported directly by Medifast in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsAndShortTermInvestments.

The official record: Medifast’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Medifast's cash cash equivalents and short term investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Medifast's cash cash equivalents and short term investments?: Medifast (MED) reported cash cash equivalents and short term investments of $168.44M in Q1 2026.
How has Medifast's cash cash equivalents and short term investments changed year-over-year?: Medifast's cash cash equivalents and short term investments increased by 0.8% year-over-year, from $167.14M to $168.44M.
What is the long-term trend for Medifast's cash cash equivalents and short term investments?: Over 3 years (2022 to 2025), Medifast's cash cash equivalents and short term investments has grown at a 23.8% compound annual growth rate (CAGR), from $87.69M to $166.35M.